Consumer medicine information

Diacol

Dibasic sodium phosphate + Sodium phosphate

BRAND INFORMATION

Brand name

Diacol

Active ingredient

Dibasic sodium phosphate + Sodium phosphate

Schedule

S3

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Diacol.

What is in this leaflet

This leaflet answers some common questions about Diacol®.

It does not contain all the information that is known about Diacol®. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor or pharmacist has weighed the risks of you taking Diacol® against the benefits it is expected to have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What Diacol® is used for

Diacol® belongs to a group of medicines that are described as purgatives (very strong laxatives). Purgatives are used to clean the bowel. They work by causing large amounts of water to be drawn into the bowel, which results in diarrhoea.

Diacol® is used in patients (adults 18 years or older) who need to have their bowel examined (by procedures such as colonoscopy). The bowel needs to be clean before your doctor can examine it properly.

Your doctor may have prescribed Diacol® for another reason. Ask your doctor if you have any questions about why Diacol® has been prescribed for you.

However, laxatives and purgatives (like Diacol®) as a group have the potential for abuse by persons with eating disorders who ‘binge’ and ‘purge’.

Before you take Diacol®

When you must not take it

Do not take Diacol® if you have an allergy to:

  • Any of the ingredients listed at the end of this leaflet
  • Any similar medicines to Diacol®

Symptoms of an allergic reaction may include:

  • Shortness of breath
  • Wheezing or difficulty breathing
  • Swelling of the face, lips, tongue or other parts of the body
  • Skin rash, itching or hives

Do not take Diacol® if you have, or have had, any of the following medical conditions:

  • Heart disease
  • Chest pain
  • Perforated bowel
  • Bowel problems such as blockages or constipation
  • An inflamed colon (colitis) or an enlarged colon
  • Hypomotility syndrome (infrequent passing of stools)
  • A condition called ascites which results in a fluid build-up around the stomach which causes swelling
  • Kidney Disease
  • Dehydration
  • Low sodium, calcium or potassium levels in the blood
  • High sodium or phosphate levels in the blood
  • Gastric bypass or stapling surgery
  • Imperforate anus
  • Paralytic ileus
  • Hirschprung's disease / congenital megacolon
  • Active inflammatory bowel disease

Caution should be exercised in ‘at risk’ patients such as the elderly who are more at risk of dehydration as electrolyte depletion may occur.

Diacol® is not recommended for use in children (under the age of 18), as the safety and effectiveness of Diacol® in this age group have not been established.

Do not take Diacol® after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If you take this medicine after the expiry date has passed, it may not work as well.

If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure when you should start taking Diacol®, talk to your doctor or pharmacist.

Before you start to take it

Tell your doctor or pharmacist if you have allergies to:

  • Any other medicines
  • Any other substances, such as foods, preservatives or dyes

Tell your doctor if you have or have had any medical conditions, especially the following:

  • Chronic inflammatory bowel disease
  • Liver disease
  • Recent cardiac surgery, cardiac arrest or heart problems
  • Thyroid problems
  • Seizures
  • Withdrawal from alcohol or benzodiazepines (medicines used to treat anxiety)
  • Diabetes

Also tell your doctor if you are on a low sodium diet. Diacol® contains a large amount of sodium and the product may be harmful to you.

Tell your doctor or pharmacist if you are pregnant, intend to become pregnant, are breastfeeding or intend to breastfeed. Diacol® is not generally recommended for use in pregnant women unless the benefits of treatment outweigh the risk to the unborn baby. Your doctor will discuss the possible risks and benefits of using Diacol® during pregnancy and breastfeeding.

If you are elderly, tell your doctor your age. Your doctor may need to check if it is safe for you to take Diacol®.

Tell your doctor if you are diabetic. The liquid diet recommended with this medication may affect your blood glucose levels and adjustment of your diabetic medication may be required.

If you have not told your doctor or pharmacist about any of the above, tell them before you start taking Diacol®.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

These include:

  • Calcium channel blockers (for angina and heart conditions)
  • Diuretics (water tablets)
  • Lithium (for mental illness)
  • Other medicines that may affect electrolyte balance
  • Other bowel cleansing preparations.
  • Non-steroidal anti-inflammatory drugs (for pain relief, swelling and other symptoms of inflammation, including arthritis)
  • ACE Inhibitors (for high blood pressure and some other heart conditions)
  • Angiotensin receptor blockers

These medicines may be affected by Diacol®, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines. Your doctor or pharmacist will advise you.

Medications that are taken just before or during the course of Diacol® may not be absorbed. This is due to the increased movement in the digestive tract and the watery diarrhoea that is caused by Diacol®.

These include:

  • Oral contraceptives (“the pill”)
  • Antibiotics
  • Medicines for diabetes

Your doctor and pharmacist may have more information on medicines to be careful with or avoid while taking Diacol®.

How to take Diacol®

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

If you do not understand the instructions on the bottle or in this leaflet, ask your doctor or pharmacist for help.

How much to take

The usual adult dosage of Diacol® taken for colon cleansing is 32 tablets to be taken as 2 lots, one of 20 tablets and one of 12 tablets.

How to take it

Because of the way Diacol® works, you must not eat any food at least 12 hours before you take the first dose of Diacol® and while you are taking the tablets. You should only drink clear liquids for 12 hours before taking Diacol® and while you are taking the tablets.

Clear liquids include strained fruit juice without pulp (apple, white grape, orange), water, clear broth, coffee or tea (without milk or non-dairy creamer) and all of the following that are not coloured red or purple: non-carbonated soft drinks, fruit flavoured cordials, clear ice blocks.

When to take it

In the evening on the day before the procedure, 4 tablets should be taken with at least one full glass of water (250mL) every 15 minutes for a total of 20 tablets. DO NOT TAKE MORE THAN 20 TABLETS.

On the day of the procedure (starting 3 – 5 hours before the procedure), 4 tablets should be taken with at least a full glass of water (250mL) every 15 minutes for a total of 12 tablets. DO NOT TAKE MORE THAN 12 TABLETS.

REMEMBER you need to be close to toilet facilities whilst you are taking Diacol®. Bowel movements may continue for several hours after the last dose of Diacol® has been taken.

Do NOT take additional laxatives or purgatives, particularly those containing sodium or phosphate.

You may see undigested or partially digested tablets in the watery diarrhoea stools.

How long to take it

Take Diacol® as prescribed by your doctor on the evening before and on the morning of the procedure. Do not take more than a total of 32 tablets.

If you forget to take it

Do not take a double dose to make up for forgotten individual doses. Take your next dose of Diacol® as soon as you remember and continue taking the tablets every 15 minutes until you have completed the course.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (Tel 131 126), or go to the Emergency Department at your nearest hospital, if you think that you or anyone else may have taken too much Diacol®. Do this even if there are no signs of discomfort or poisoning.

You may need urgent medical attention.

If you take too much Diacol®, you may feel dehydrated, light-headed or dizzy.

While you are taking Diacol®

Things you must do

Diacol® can lead to serious dehydration and electrolyte disturbances. You must ensure that you drink the recommended amount of liquid to replace the large amounts of fluid that may be lost during bowel emptying. Ask your doctor or pharmacist to answer any questions you may have.

Things you must not do

Do not repeat the course of Diacol® for at least seven days. No other laxative, enema or other medication containing sodium phosphate should be taken.

Do not give Diacol® to anyone else, even if they have the same condition as you.

Do not take Diacol® to treat any other complaints unless your doctor or pharmacist tells you to.

Do not stop taking Diacol®, or lower the dosage, without checking with your doctor or pharmacist.

Things to be careful of

Do not attempt to drive or operate machinery during the treatment with Diacol®. It will be impractical for you to drive or operate machinery since you will have to stay close to a toilet until the purgative effect is complete. Diacol® may also make you feel light headed or dizzy or drowsy, which would make driving or operating machinery dangerous if you are affected.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Diacol®. Diacol® helps most people that require bowel cleansing, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not.

If you are over 65 years of age you may have an increased chance of getting side effects.

Ask your doctor or pharmacist to answer any questions you may have.

Diacol® may cause a number of diarrhoea like bowel movements. This is normal and is a result of its bowel-cleansing action. You should not be alarmed by this, but should continue to drink the recommended amount of clear fluids to prevent dehydration.

The following is a list of possible side effects. Tell your doctor or pharmacist if you notice any of the following and they worry you:

  • Nausea (feeling sick)
  • Vomiting
  • Stomach pain
  • Stomach bloating
  • Dizziness
  • Headache
  • Light headed
  • Drowsiness
  • Signs of dehydration such as feeling thirsty and urinating less often

Do not be alarmed by this list. You may not experience any of them.

If the effects are severe, you may need medical treatment.

However, these side effects usually disappear within several hours of finishing Diacol® treatment.

If you get any side effects, do not stop taking Diacol® without first talking to your doctor or pharmacist.

Other side effects not listed above may also occur in some patients. Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

After using Diacol®

Storage

Keep your tablets in the bottle until it is time to take them. If you take the tablets out of the bottle they will not keep well.

Keep your tablets in a cool dry place where the temperature stays below 25°C. Keep the container tightly closed.

Do not store Diacol® or any other medicine in the bathroom or near a sink.

Do not leave it on a window sill or in the car on hot days. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor or pharmacist tells you to stop taking Diacol® or the tablets have passed their expiry date, ask your pharmacist what to do with any that are left over.

Product description

What it looks like

Diacol® Tablets are oval, white to off white, “SLX” bisect “102” on one side and plain on the other side.

Diacol® is available in bottles of 32 tablets. Each bottle contains 2 silica desiccant packets which are not to be consumed.

Ingredients

Active ingredients:

  • Monobasic sodium phosphate (1102mg per tablet)
  • Dibasic sodium phosphate (398mg per tablet)

Other ingredients:

  • Magnesium stearate
  • Polyethylene glycol 8000

Diacol® does not contain lactose, sucrose, gluten, tartrazine or any azo dyes.

Supplier

Diacol® is supplied by:

Fresenius Kabi Australia Pty Limited
Level 2, 2 Woodland Way, Mount Kuring-gai NSW 2080, Australia
Telephone: (61-2) 9391 5555

This leaflet was prepared on 15 April 2016.

Australian Registration Number:

AUST R 149914

Diacol® is a trademark of Fresenius Kabi Australia Pty Limited

Published by MIMS September 2019

BRAND INFORMATION

Brand name

Diacol

Active ingredient

Dibasic sodium phosphate + Sodium phosphate

Schedule

S3

 

Name of the medicine

Monobasic sodium phosphate USP, dibasic sodium phosphate USP.

Excipients

Polyethylene glycol 8000 (PEG) and magnesium stearate.

Description

Monobasic sodium phosphate.

Molecular formula: NaH2PO4.H2O. MW: 137.99. CAS: 10049-21-5. Monobasic sodium phosphate is a white, colourless, slightly hygroscopic crystal or granule, which is freely soluble in water and practically insoluble in alcohol.

Dibasic sodium phosphate.

Molecular formula: Na2HPO4. MW: 141.96. CAS: 7558-79-4. Dibasic sodium phosphate is a white odourless, hygroscopic powder, which is soluble in approximately eight parts of water and is much more soluble in hot water.

Pharmacology

Pharmacological actions.

Diacol is a bowel evacuant used to clean the colon prior to diagnostic procedures such as colonoscopy.
Diacol, a dosing regime containing 48 g of sodium phosphate (32 tablets), induces a diarrhoea, which rapidly and effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. The primary mode of action is thought to be through osmotic action of sodium, causing large amounts of water to be drawn into the bowel. The influx of water stimulates bowel evacuation, rapidly and effectively cleansing the entire colon.

Pharmacokinetics.

Approximately 60-65% of ingested dietary phosphate is absorbed from the gastrointestinal tract via an active energy dependant process. Phosphate distributes into plasma and extracellular fluid, cell membranes and intracellular fluids. More than 90% of plasma phosphate is filtered and 80% of the filtered phosphate is actively reabsorbed in the steady state.
Twenty-three normal healthy volunteer subjects participated in an open label pharmacokinetic study of sodium phosphate tablets designed to generate concentration time curves for serum inorganic phosphorus levels after administration of the sodium phosphate tablets. Subjects were administered sodium phosphate tablets consistently with the prescribed labeling for colon cleansing. A 30 g dose (20 tablets given as three tablets every 15 minutes with clear liquids) was given beginning at 6 pm in the evening. The 30 g dose (20 tablets given as three tablets every 15 minutes with clear liquids) was repeated the following morning beginning at 6 am. The serum phosphorus level rose to a maximum mean (± standard deviation) peak of 3.7 ± 1.63 mg/dL above baseline, at a median of 3 hours after the first administration of sodium phosphate tablets. Following the second administration of sodium phosphate tablets the serum phosphorus level rose to a maximum mean (± standard deviation) peak of 4.4 ± 1.86 mg/dL above baseline, at a median of 4 hours. (See Figure 1.)
The serum phosphorus level remained above baseline for a median of 24 hours after the initial dose of sodium phosphate tablets (range 16 to 48 hours), with a maximum mean decrease of 18 hours in serum calcium of 0.3 mg/dL ± 0.03 mg/dL.

Special populations.

Renal insufficiency.

The effect of renal dysfunction on Diacol pharmacokinetics has not been studied. Since the ionised, inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys, patients with renal disease may have difficulty excreting a large phosphate load. Thus, Diacol should be used with caution in patients with impaired renal function.

Hepatic insufficiency.

Diacol has not been investigated in patients with hepatic failure. The ionised, inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys. Diacol is not expected to be metabolised in the liver.

Geriatric.

Both AUC and Cmax values of serum phosphate were less than half in subjects > 70 years of age compared to subjects < 70 years of age, based on the results of a single pharmacokinetic study, which included 6 elderly volunteers. Plasma half-life increased twofold in subjects > 70 years of age compared to subjects < 50 years of age (3 subjects and 5 subjects, respectively).

Gender.

No difference in serum phosphate AUC values were observed in the single pharmacokinetic study conducted in 13 male and 10 female healthy volunteers.

Clinical Trials

A total of 957 adult patients were enrolled and treated in controlled clinical trials of sodium phosphate tablets. Sodium phosphate tablets were found to be comparable in cleansing efficacy to the comparison drug, a commercially available polyethylene glycol salt (PEG salt solution) solution (cherry flavour NuLytely). Two identical, single (investigator) blind, randomised, multicentre trials were conducted comparing the efficacy and safety of sodium phosphate tablets and the PEG salt solution comparator as a colon cleansing agent in patients undergoing routine diagnostic colonoscopy.
The efficacy of overall colonic cleansing with the sodium phosphate tablets was comparable to the PEG salt solution. In addition, the incidence of ‘inadequate’ colon cleansing ratings due to poor purgative preparation was similar between sodium phosphate tablets and the PEG salt solution comparator. Also, cleansing efficacy in the ascending colon with sodium phosphate tablets was comparable to the PEG salt solution.
A total of 1055 patients were enrolled and treated in controlled clinical trials of sodium phosphate tablets that included Diacol as the test drug. In a phase III clinical study 816 patients were enrolled and treated, studying the colon cleansing efficacy and safety of Diacol compared to another sodium phosphate tablet studied previously (see above).
In the phase III trial (INKP-102-04-01), patients were randomised into one of the following three sodium phosphate treatment groups:
1) sodium phosphate tablets containing 60 g of sodium phosphate given in split doses (30 g in the evening before the colonoscopy and 30 g on the next day) with at least 3.5 L of clear liquids;
2) Diacol containing 60 g of sodium phosphate given in split doses (30 g in the evening before the colonoscopy and 30 g on the next day) with 2.5 L of clear liquids; and
3) Diacol containing 48 g of sodium phosphate (30 g in the evening before the colonoscopy and 18 g on the next day) with 2 L of clear liquids.
The primary efficacy endpoint was the overall colon cleansing response rate in the 4 point colonic contents scale. Response was defined as a rating of ‘excellent’ or ‘good’ on the 4 point scale as determined by the blinded colonoscopist. This phase III study was planned to assess the noninferiority of the two Diacol groups compared to the sodium phosphate tablet group.
Patients ranged in age from 21 to 89 years old (mean age 56 years old) with 55% female and 45% male patients. The Diacol 60 g and 48 g treatment groups demonstrated noninferiority compared to sodium phosphate tablets. See Table 1 for the results.

Indications

Diacol is indicated for cleansing of the bowel when required as a preparation for certain diagnostic procedures such as colonoscopy.

Contraindications

Diacol is not to be used in patients with renal insufficiency, potentially pre-existing fluid/ electrolyte disturbance, congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome (associated with, e.g. scleroderma, inadequately treated hypothyroidism).
Other contraindications to this class of treatment are faecal impaction, Hirschsprung's disease (congenital megacolon), imperforate anus, and patients at risk of dehydration due to altered senses and/or poor fluid intake.
Diacol is contraindicated in patients with known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.

Warnings

Life threatening dehydration and/or electrolyte disturbances may occur in ‘at risk’ groups (see Contraindications and Precautions).
Nephrocalcinosis associated with transient renal insufficiency and renal failure has been very rarely reported in patients using sodium phosphates for bowel cleansing; the majority of these reports occurred in elderly female patients taking drugs to treat hypertension or other drug products, such as diuretics or NSAIDs that may result in dehydration. Patients with conditions that may predispose to dehydration or those taking medications which may decrease glomerular filtration rate, such as diuretics, angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or nonsteroidal anti-inflammatory drugs (NSAIDs) should be assessed for hydration status prior to use of purgative preparations and managed appropriately. Care should be taken to prescribe Diacol per recommendations with particular attention to known contraindications and adequate hydration.

Precautions

Administration of sodium phosphate containing products, such as enemas or nonprescription liquid purgatives, has resulted in fatalities due to significant fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias. These have been observed in patients with renal insufficiency or bowel perforation, and with misuse or overdose of these products.
Use with caution in diabetic patients as the recommended liquid diet during the period of administration prior to the procedure may affect blood glucose levels, requiring adjustment of antidiabetic medication or insulin.
Also use with caution in patients taking drugs that may affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatraemia, hyperphosphataemia, hypokalaemia or hypocalcaemia should have them corrected before treatment with Diacol.
Patients should be instructed to drink sufficient quantities of clear liquids or water with administration of Diacol. Inadequate fluid intake, as with any effective purgative, may lead to excessive fluid loss and hypovolaemia.
Undigested or partially digested tablets may be seen in the watery diarrhoea stool or during colonoscopy. In addition, undigested tablets from other medications may be seen.
Patients should be instructed not to administer additional agents, particularly additional sodium phosphate based purgative or enema products.
Prolongation of the QT interval has been observed in some patients who were dosed with Diacol. QT prolongation with Diacol has been associated with electrolyte imbalances, such as hypokalaemia and hypocalcaemia. Diacol should be used with caution in patients who are taking medications known to prolong the QT interval, since serious complications may occur. In these studies, prolongation of the QT interval was also observed in some patients treated with PEG salt solution.
There have been reports of generalised tonic/ clonic seizures and/or loss of consciousness associated with Diacol use in patients with no prior history of seizures. Cases of seizure were associated with electrolyte abnormalities (e.g. hyponatraemia, hypokalaemia, hypochloraemia, hypocalcaemia, hypomagnesaemia) and low serum osmolality. Neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities. Other purgatives, including sodium phosphate solution and PEG 3350 containing products, have also been associated with seizures and alterations of consciousness in patients with and without a prior history of seizures. Most patients with hyponatraemia associated with Diacol use had one or more pre-existing risk factors for hyponatraemia, including chronic use of other medications associated with hyponatraemia or seizures (i.e. tricyclic antidepressants such as nortriptyline or a PEG laxative), prior history of hyponatraemia associated with purgation, or excessive ingestion of fluids. Diacol should be used with caution in patients with risk factors of hyponatraemia, e.g. SIADH, a history of electrolyte abnormalities, inadequately treated hypothyroidism, use of other drugs associated with hyponatraemia, e.g. thiazide diuretics, or adrenal insufficiency, or with risk factors for development of tonic/ clonic seizures, e.g. a history of seizures, use of drugs that lower the seizure threshold such as tricyclic antidepressants, or withdrawal from alcohol or benzodiazepines.
Administration of Diacol may induce colonic mucosal aphthous ulcerations, an endoscopic finding observed with other sodium phosphate cathartic preparations. This colonscopic finding should be considered in patients with known or suspected inflammatory bowel disease.
Because published data suggest that sodium phosphate absorption may be enhanced in patients experiencing an acute exacerbation of chronic inflammatory bowel disease, Diacol should be used with caution in such patients.
Diacol was not studied in patients within 3 months of an acute myocardial infarction or cardiac surgery, including coronary artery bypass graft surgery, and therefore should be used with caution in such patients.
Diacol has not been investigated in patients with hepatic failure. The ionised, inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys. Diacol is not expected to be metabolised in the liver.

Effects on fertility.

Studies to evaluate the effect of Diacol on fertility or its mutagenic potential have not been performed.

Use in pregnancy.

Use in pregnancy and lactation.

No animal reproductive studies have been conducted with Diacol. It is not known whether Diacol can cause harm to the unborn foetus if administered to a pregnant woman or interfere with reproductive capacity. Diacol should only be given to pregnant or breastfeeding women if the benefits clearly outweigh the possible risks.

Use in lactation.

See Use in Pregnancy.

Paediatric use.

Safety and efficacy of Diacol have not been demonstrated for patients less than 18 years of age.

Use in the elderly.

Of the total number of subjects in controlled phase II and III clinical studies (INKP-102-04-01 and INKP-102-03-01) of Diacol, 19.6% were over 65, while 5.2% were over 75. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, greater sensitivity of some older individuals cannot be ruled out. Diacol should be used with caution in elderly patients.
Sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. Elderly patients are more likely to have impaired renal function, and it may be useful to assess renal function.

Carcinogenicity.

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Diacol.

Genotoxicity.

Studies to evaluate the effect of Diacol on fertility or its mutagenic potential have not been performed.

Drug abuse and dependence.

Under the direction of a physician, Diacol is indicated for cleansing of the bowel when required as a preparation for diagnostic procedures such as colonoscopy, in adults aged 18 years or older. Laxatives and purgatives as a group have the potential for abuse by persons with eating disorders who binge and purge.

Preparative diet.

Because of the mechanism of action of Diacol, patients should be advised to take only clear liquids by the mouth for at least 12 hours prior to starting the purgative regimen.

Effects on ability to drive and use machines.

Diacol may cause dizziness and drowsiness affecting the ability to drive or operate machinery.

Interactions

No drug interaction studies have been conducted for Diacol. As with other purgatives the absorption of other orally administered medicines (e.g. oral contraceptives, antibiotics, and antidiabetics) may be delayed or completely prevented.
Care should be taken with patients taking calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), nonsteroidal anti-inflammatory drugs (NSAIDs) and lithium preparations or other medications that might affect electrolyte levels as hyperphosphataemia, hypocalcaemia, hypernatraemic dehydration and acidosis may occur.
Concurrent administration of polyethylene glycol bowel cleansing preparations and Diacol may be dangerous and is not recommended (see Adverse Effects).

Adverse Effects

Although these reactions have not been observed to date with Diacol, there have been reports to the Australian Adverse Drug Reactions Advisory Committee of severe adverse events and fatalities in ‘at risk’ groups with other sodium phosphate based purgatives.
The most commonly observed adverse reactions (incidence ≥ 1%, all treated patients) occurring with the use of Diacol are related to the desired purgative effect. Nausea, vomiting, abdominal bloating, abdominal pain, dizziness, and headache occur, and are generally transient and self limited, requiring no specific treatment. All of these adverse events also occurred in patients who took the PEG salt solution comparator. Small superficial mucosal ulcerations, typical of those previously reported from the use of liquid preparations of sodium phosphate, and instances of mucosal bleeding have been observed on colonoscopy.
One patient, with no history of heart disease, developed an initial episode of atrial fibrillation after severe vomiting immediately after taking Diacol. Another patient, with known arteriosclerotic heart disease, who took the PEG salt solution comparator developed atrial fibrillation and also vomited. No patient in the clinical studies developed predefined postural changes in vital signs with concomitant symptoms of lightheadedness or syncope.

Electrolyte changes.

Serum electrolyte changes have been observed in patients taking Diacol primarily affecting calcium, phosphate and potassium. These changes essentially corrected within 48 to 72 hours after dosing, were not associated with any clinical adverse events and did not require treatment. No patient developed clinically significant hypocalcaemia; among patients receiving Diacol 60 g (n = 481), the mean decrease from baseline in calcium level was 0.5 mg/dL. No patient developed a calcium level below 7.1 mg/dL. No clinical adverse events suggestive of hypocalcaemia were observed. Mean serum phosphorus levels increased by approximately 3.6 mg/dL transiently after taking Diacol with no apparent clinical significance. A reactive decrease in serum phosphorus 2-3 days after dosing was observed; the mean decrease from baseline at that time was 0.7 mg/dL. The mean decrease in serum potassium after taking Diacol was 0.5 mEq/L.

Dosage and Administration

Patients are required to drink only clear fluids for 12 hours before taking the first dose of Diacol.
The usual dosage of Diacol for colon cleansing is 32 tablets taken orally in the following manner.

Adults (over 18 years of age).

The evening before the procedure, 4 tablets should be taken with at least 250 mL of water or clear liquids every 15 minutes for a total of 20 tablets. The day of the procedure (starting 3-5 hours before the procedure), 4 tablets should be taken with at least 250 mL of clear liquids or water every 15 minutes) for a total of 12 tablets.
Clear liquids include strained fruit juice without pulp (apples, white grape, orange), water, clear broth, coffee or tea (without milk or nondairy creamer) and all of the following that are not coloured red or purple: noncarbonated soft drinks, fruit flavoured cordials, clear ice blocks.
Patients are not to repeat this purgative agent within seven days of a previous administration. No additional enema or laxative is required, and patients should be advised not to take additional agents, particularly those containing sodium phosphate.

Renal insufficiency.

Diacol should be used with caution in patients with impaired renal function (see Pharmacology, Pharmacokinetics and Precautions).

Hepatic insufficiency.

Diacol has not been investigated in patients with hepatic failure (see Pharmacology, Pharmacokinetics and Precautions).

Overdosage

There have been no reported cases of overdosage with Diacol. Purposeful or accidental ingestion of more than the recommended dosage of Diacol may result in severe electrolyte disturbances, including hyperphosphataemia, hypocalcaemia, hypernatraemia or hypokalaemia, as well as dehydration and hypovolaemia, with attendant signs and symptoms of these disturbances. Certain severe electrolyte disturbances may lead to cardiac arrhythmias and death. The patient who has taken an overdosage should be monitored carefully, and treated symptomatically for complications until stable.

Presentation

Tablets, monobasic sodium phosphate 1.102 g and dibasic sodium phosphate 0.398 g (white to off white, oval, scored, marked SLX/102, plain on reverse): 32's (child resistant bottle, AUST R 149914).

Storage

Store below 25°C. Keep container tightly closed.
Discard any unused portion.

Poison Schedule

S3.